FDA Requires New Class Warning for mRNA COVID-19 Vaccines: Myocarditis/Pericarditis Update (June 2025)

Meta title (≤60 chars): FDA adds myocarditis warning to mRNA COVID-19 shots
Meta description (≤155 chars): FDA now requires updated warnings on Pfizer and Moderna mRNA COVID-19 vaccines, with new incidence estimates and post-marketing findings.

TL;DR

What changed: FDA required and approved updates to the Prescribing Information (PI) for Comirnaty® (Pfizer/BioNTech) and Spikevax® (Moderna) to expand the myocarditis/pericarditis warning and add new safety data. U.S. Food and Drug Administration
Key numbers now on label: ~8 cases per million doses (all ages 6 months–64, within 7 days after 2023–24 formula); highest in males 16–25 years (~38/million). U.S. Food and Drug Administration+1
New text also references: persistence of cardiac MRI abnormalities at ~5-month follow-up in a post-approval cohort; clinical significance unknown. U.S. Food and Drug Administration+1
Scope: PI Warnings & Precautions (5.2) and Adverse Reactions (6.2); patient/recipient information; EUA Fact Sheets for 6 months–11 years were aligned. U.S. Food and Drug Administration
Why now: FDA invoked FDCA §505(o)(4) to mandate a Safety Labeling Change (SLC) based on new safety information from BEST insurance-claims analyses and a post-approval study. U.S. Food and Drug Administration+1

What exactly did FDA do?

Issued Safety Communication (June 25, 2025): Publicly announced that both manufacturers must add new incidence estimates and post-marketing study outcomes to labeling (HCP and patient materials). Content current as of 06/25/2025. U.S. Food and Drug Administration
Sent formal SLC letters (April 17, 2025) to Moderna and Pfizer/BioNTech under FDCA §505(o)(4) requiring:
- Update Warnings & Precautions (5.2) to state highest estimated incidence in males 16–25 and to include incidence ~8/million across 6 months–64 years, 1–7 days post-dose (2023–24 formula).
- Add Adverse Reactions (6.2) language summarizing post-approval study showing persistent cardiac MRI abnormalities at ~5 months; prognostic significance unknown.
- Deadline: 30 calendar days to submit a labeling supplement (CBE-0 if identical text; PAS if different) or submit a rebuttal; failure can lead to misbranding and civil monetary penalties. U.S. Food and Drug Administration+1
Aligned EUA fact sheets for pediatric formulations (6 months–11 years) with the revised PI language. U.S. Food and Drug Administration

The new label language—what’s different?

Incidence statement (new):
“Based on analyses of commercial health insurance claims data from inpatient and outpatient settings, the estimated incidence of myocarditis and/or pericarditis during the period 1–7 days following administration of the 2023–2024 formula of mRNA COVID-19 vaccines in individuals 6 months–64 years was ~8 cases per million doses. The highest estimated incidence was in males 16–25 years (~38 per million).” U.S. Food and Drug Administration+1
Post-approval study summary (new):
In a multicenter cohort of patients (primarily after dose 2) with vaccine-associated myocarditis, persistent cardiac MRI abnormalities consistent with myocardial injury were common at a median ~5 months; clinical/prognostic significance unknown. U.S. Food and Drug Administration+1
Placement: This content is now in Warnings & Precautions (5.2) and cross-referenced in Adverse Reactions (6.2), and reflected in Information for Recipients & Caregivers. U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2

Why the update now?

FDA determined new safety information met the threshold for a mandated SLC:

BEST claims analyses quantifying age/sex-specific incidence with the 2023–24 formulation.
Longitudinal outcomes showing persistent CMR abnormalities after vaccine-associated myocarditis (prognosis not yet established).
Together, these strengthened transparency and risk communication without changing the overall assessment that myocarditis/pericarditis events are rare. U.S. Food and Drug Administration+1

What should clinicians do now? (Practical points)

Inform and document: Discuss the rare risk, emphasize highest risk in males 16–25, and note typical onset within 7 days. Provide return precautions for chest pain, dyspnea, palpitations. U.S. Food and Drug Administration+1
Evaluate suspected cases per cardiology guidance (troponin, ECG, echo; consider CMR).
Report to VAERS; share outcomes (including follow-up MRI if performed). U.S. Food and Drug Administration
Pediatric counseling: EUA Fact Sheets for 6 months–11 years now mirror the new safety language—ensure caregivers receive the updated version. U.S. Food and Drug Administration

Manufacturer playbook: what to update, by when

1) Labeling & regulatory (time-sensitive)

Submit the SLC within 30 days of the FDA letters (or submit a rebuttal). Use CBE-0 if adopting FDA-specified text verbatim; PAS if proposing alternatives. Non-compliance risks misbranding and civil monetary penalties. U.S. Food and Drug Administration+1
Update PI Sections:
- Highlights → Recent Major Changes reference to 5.2.
- Warnings & Precautions (5.2) → incidence (8/million; 16–25 highest at ~38/million) and post-approval CMR findings language.
- Adverse Reactions (6.2) → post-marketing experience summary of the cohort study. U.S. Food and Drug Administration+1
Synchronize Information for Recipients & Caregivers and US websites/IFUs; mirror updates in EUA Fact Sheets for pediatric ages. U.S. Food and Drug Administration

2) Medical affairs & HCP communication

Issue a Dear HCP letter summarizing: new risk estimates, highest-risk demographic, typical timing, and evaluation/reporting steps.
Refresh slide decks and detail aids with the 1–7 day window and 16–25 male peak; include QR codes to VAERS and revised PI. U.S. Food and Drug Administration+1

3) PV & signal management

Ensure case definitions/coding capture myocarditis/pericarditis; track time-to-onset (≤7 days), dose number, sex/age, CMR results, and recovery timeline.
Update RMP/periodic safety reports with age-sex incidence stratification reflecting 2023–24 formula and longitudinal outcomes. U.S. Food and Drug Administration+1

4) Commercial & ops

Version-control cartons/inserts and digital copies; retrain call centers and field teams on the new incidence text and post-approval study line.
Audit downstream partners (distributors, HCP portals) to ensure updated documents are live.

Key numbers and phrases to quote accurately

“~8 cases per million doses” (1–7 days after 2023–24 formula; ages 6 months–64).
“Highest in males 16–25 years (~38 per million)”.
“Persistence of cardiac MRI abnormalities at ~5 months; clinical significance unknown.”
All of the above are verbatim concepts extracted from FDA’s SLC letters and must appear in 5.2 and 6.2 of the PI. U.S. Food and Drug Administration+1

Background & context

Label warnings since 2021: Myocarditis/pericarditis risks have been on label for years; the 2025 action expands and standardizes the language using new data. U.S. Food and Drug Administration
Ongoing monitoring: FDA continues post-market surveillance and requires manufacturers to incorporate new safety information under §505(o)(4) when warranted. U.S. Food and Drug Administration+1

Frequently asked (publish-ready)

Is the risk common?
No. It remains rare overall; the peak is in males 16–25 and still on the order of tens per million doses. U.S. Food and Drug Administration+1

When does it happen if it happens?
Most cases occur within 7 days after vaccination. U.S. Food and Drug Administration+1

What’s new about severity/outcomes?
FDA highlights a study where CMR abnormalities persisted at ~5 months; we don’t yet know what that means long-term. U.S. Food and Drug Administration+1

Do pediatric fact sheets change?
Yes—EUA Fact Sheets for 6 months–11 years now include the aligned safety language. U.S. Food and Drug Administration

Sources & documents

FDA Safety Communication (6/25/2025): summary of actions, scope, and materials updated. U.S. Food and Drug Administration
FDA SLC Letter—Comirnaty (4/17/2025): mandated wording, incidence numbers, 30-day response, penalties. U.S. Food and Drug Administration
FDA SLC Letter—Spikevax (4/17/2025): identical structure/requirements. U.S. Food and Drug Administration
CBER 2025 Safety & Availability archive: confirms the action and date. U.S. Food and Drug Administration

Discover more from सुदर्शन

Subscribe to get the latest posts sent to your email.